# Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

> **NCT02597361** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 61 (actual)

## Conditions studied

- Ehlers-Danlos Syndrome, Vascular Type

## Interventions

- **DRUG:** Irbesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02597361
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2020-02-19
- **Final completion:** 2020-02-19
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597361, "Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02597361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*